Proteus Digital Health™ is pioneering a new category of products, services and data systems based on integrating medicines with ingestible, wearable, mobile and cloud computing.
Its core technology – the digital health feedback system – provides an unprecedented view into an individual’s personal health choices and physiologic response, allowing patients to better manage their health and more effectively collaborate with caregivers and clinicians, while enabling new information-based business models.
Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for its wearable and Ingestible Sensor™ devices. Headquartered in Redwood City, Calif., Proteus is privately held and funded by Carlyle, Essex Woodlands, Kaiser Permanente®, Medtronic®, Novartis®, Otsuka®, Oracle®, ON Semiconductor® and other investors.
Source: Company Press Release
*Based on Preferred Stock Price, Proteus Digital Health does not have a stock symbol since it is currently private and is yet to have an IPO.
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Proteus Digital Health or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.